




RealRate

# PHARMACEUTICAL 2018

Ampio Pharmaceuticals Inc  
Rank 322 of 332

Ampio  
PHARMACEUTICALS



The relative strengths and weaknesses of Ampio Pharmaceuticals Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Ampio Pharmaceuticals Inc compared to the market average is the variable Expenses, increasing the Economic Capital Ratio by 13% points. The greatest weakness of Ampio Pharmaceuticals Inc is the variable Stockholders Equity, reducing the Economic Capital Ratio by 144% points.

The company's Economic Capital Ratio, given in the ranking table, is 42%, being 210% points below the market average of 252%.

| Input Variable                              | Value in<br>1000 USD |
|---------------------------------------------|----------------------|
| Assets, Current                             | 8,443                |
| Cost of Goods Sold                          | 0                    |
| Intangible Assets                           | 0                    |
| Liabilities, Current                        | 3,878                |
| Liabilities, Non-Current                    | 0                    |
| Other Assets                                | 34                   |
| Other Compr. Net Income                     | 0                    |
| Other Expenses                              | 10,421               |
| Other Liabilities                           | 45,613               |
| Other Net Income                            | -36,327              |
| Other Revenues                              | 0                    |
| Property and Equipment                      | 6,838                |
| Research and Development                    | 0                    |
| Selling, General and Administrative Expense | 5,144                |

| Output Variable             | Value in<br>1000 USD |
|-----------------------------|----------------------|
| Assets                      | 15,315               |
| Liabilities                 | 49,491               |
| Expenses                    | 15,565               |
| Revenues                    | 0                    |
| Stockholders Equity         | -34,177              |
| Net Income                  | -51,892              |
| Comprehensive Net Income    | -51,892              |
| BaseVar                     | 58,349               |
| ECR before LimitedLiability | -390%                |
| Economic Capital Ratio      | 42%                  |